Fig. 8: Anticancer performance assessment.

a–c Cell viability of compounds 3a, 3n, and 4a (n = 5 biologically independent samples). d–f Confocal images of 4T1 cells stained with DCFH-DA and calcein-AM/PI after treatment with various doses of compounds 3a, 3n, and 4a. g–i Flow cytometry analysis of apoptotic cells after treatment with different concentrations of compounds 3a, 3n, and 4a.